EI
XERS icon

EAM Investors’s Xeris Biopharma Holdings XERS Stock Holding History

EAM Investors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-80,154
Closed -$629K – 389
2025
Q4 		$629K Sell
80,154
-522,947
-87% -$4.12M 0.07% 248
2025
Q3 		$4.85M Buy
603,101
+16,236
+3% +$108K 0.56% 68
2025
Q2 		$2.74M Sell
586,865
-347,781
-37% -$1.59M 0.42% 121
2025
Q1 		$5.13M Buy
934,646
+712,269
+320% +$2.88M 0.89% 8
2024
Q4 		$754K Buy
+222,377
New +$715K 0.11% 223
2023
Q3 		– Sell
-757,962
Closed -$1.99M – 393
2023
Q2 		$1.99M Buy
+757,962
New +$1.93M 0.37% 105

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM Investors's XERS Position: Q1 2026 in Review

EAM Investors sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 80,154 shares — an estimated $629K sold.

EAM Investors first reported a position in XERS in Q2 2023 and held it in 6 quarters. The position peaked at $5.13M in Q1 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • EAM Investors reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 80,154 Xeris Biopharma Holdings shares in Q1 2026, an estimated $629K.
  • EAM Investors first reported a position in Xeris Biopharma Holdings in Q2 2023 and held it in 6 quarters.
  • EAM Investors's Xeris Biopharma Holdings position peaked at $5.13M in Q1 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.